Biomay, Synthego partner to streamline cGMP CRISPR manufacturing services. Collaboration combines mRNA, Cas9, LNP formulation, and sgRNA expertise to accelerate gene-editing programs in North America. October 1, 2026 Associate Editor, Contract Pharma Biomay and Synthego have entered a non-exclusive collaboration aimed at simplifying access to critical gene-editing materials and cGMP manufacturing services for customers across North America. Under the agreement, Biomay will market, promote, and resell its portfolio of products and services to Synthego customers, creating a more integrated pathway for organizations developing CRISPR-based therapies. The collaboration combines Biomay's expertise in mRNA manufacturing, lipid nanoparticle (LNP) formulation, aseptic fill-finish, plasmid DNA, recombinant proteins, and Cas9 production with Synthego's capabilities in CRISPR gene-editing solutions and single-guide RNA (sgRNA) design and manufacturing. The collaboration is designed to help developers accelerate CRISPR programs by providing streamlined access to key components and manufacturing capabilities required for gene-editing applications. As part of the arrangement, Synthego customers will gain access to Biomay's off-the-shelf Cas9 recombinant nuclease and Cas9-encoding mRNA products for both research-use-only and cGMP applications. The companies will also offer integrated cGMP solutions that combine Biomay's mRNA manufacturing, LNP formulation, aseptic fill-finish, and Cas9 production capabilities with Synthego's sgRNA expertise. In addition, the collaboration will support custom cGMP mRNA manufacturing services, including LNP formulation and fill-finish operations for gene-editing and other advanced therapeutic programs. "We are pleased to enter into this collaboration with a pioneering CRISPR solutions provider like Synthego," said May Guo, VP of Business Development at Biomay. "By combining our complementary capabilities, we can make it easier for customers to access the critical components and cGMP manufacturing services they need, helping them accelerate their gene-editing programs from early development toward the clinic." Hana Kim, PhD, Director of Clinical Product Management at Synthego, highlighted Biomay's experience in cGMP mRNA manufacturing and gene-editing component production, noting that the company manufactures the Cas9 nuclease used in CASGEVY, the first approved CRISPR/Cas9-based therapy. The partnership reflects growing demand for end-to-end manufacturing solutions that can support the rapid advancement of gene-editing therapies from research through clinical development. By bringing together expertise across sgRNA, Cas9, mRNA production, LNP formulation, and aseptic fill-finish, the companies aim to offer developers a more seamless route to obtaining high-quality materials and manufacturing support for CRISPR-based programs. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Base Therapeutics and KACTUS announce strategic partnership with Synthego to advance GMP AccuBase(TM) base editing platform. Home / news & articles / Base Therapeutics and KACTUS announce strategic partnership with Synthego to advance GMP AccuBase(TM) base editing platform. Base Therapeutics and KACTUS are excited to announce a strategic partnership with Synthego for the distribution of the AccuBase(TM) cytosine base editor. This collaboration aims to accelerate innovation and accessibility of next-generation cell and gene therapies. This agreement integrates Base Therapeutics' pioneering base-editing technologies, and KACTUS' leadership in enzyme design and GMP-grade production with Synthego's industry-leading RUO-to-GMP CRISPR Solutions to address unmet needs in the rapidly evolving field of genomic medicine. "We are thrilled to collaborate with Synthego and Base Therapeutics to meet the needs of our global customers and accelerate the availability of therapeutic solutions for disease treatment. Through this alliance, we aim to advance the research and industrialization of cell and gene therapy," said Edmund Wang, CEO of KACTUS. Traditional CRISPR editing systems such as Cas9 or Cas12 rely on DNA double-strand breaks, introducing risks such as chromosomal loss or translocation. In contrast, the AccuBase(TM) cytosine base editor represents "CRISPR 2.0" technology that enables ultra-precise, cell-friendly editing with near-zero off-target effects. As the only GMP-grade base editing proteins currently available, AccuBase(TM) marks a new era for gene editing, shifting from "cutting" to "precision modification". "AccuBase(TM) is the next evolution of our clinical-grade solutions, complementing our best-in-class Guide RNA with a powerful base editing platform. With over five years of proven GMP experience and regulatory guidance, we are uniquely positioned to empower our therapeutic partners and accelerate their path to the clinic," said Craig Christianson, CEO of Synthego. "This partnership represents an important milestone in the global expansion of AccuBase(TM). We look forward to working with therapeutic partners to ensure that gene-editing technologies truly benefit human health worldwide," said Dr. Tianhong Xu, Founder and CEO of Base Therapeutics. As a leading supplier in cell and gene therapy, KACTUS provides an extensive portfolio of gene-editing enzymes - including GMP-grade Cas9 (FDA DMF filed) and GMP-grade AccuBase(TM)- to support customers throughout the IND and clinical phases of drug development. By integrating their respective scientific, commercial and regulatory strengths, this strategic partnership will advance the development of next-generation gene editing technologies, establishing a new standard for safe and effective tools in therapeutic applications. About KACTUS. KACTUS is an innovation-driven company specializing in recombinant proteins and enzyme materials to support the development and manufacturing of biopharmaceuticals. Established in 2018, KACTUS has built deep expertise in protein R&D and production through its proprietary structure-designed protein platform, SAMS(TM). With its own 100,000 square foot GMP facility and certified quality system, KACTUS supplies a broad range of GMP-grade raw proteins and enzymes tailored to the needs of cell and gene therapy drug development. About Synthego. Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. Recognized in hundreds of peer-reviewed publications and trusted by thousands of researchers and therapeutic developers, Synthego is driving the future of medicine through cutting-edge genome-editing technologies. About Base Therapeutics. Founded in 2021, Base Therapeutics is a high-tech enterprise focused on breakthrough innovations in gene editing. The company holds more than 30 domestic and international patents and is developing first-in-class cell and gene-editing products, particularly in cancer and rare genetic diseases. Its pipeline includes base-editing CAR-T and in vivo base-editing therapies, as well as NK510 and NK520 programs. Base Therapeutics' NK cell base-editing therapies are already in clinical studies exploring efficacy and safety in relapsed, refractory, and metastatic solid and hematologic tumors where conventional chemotherapy has failed.